Research Progress on RET Fusion in Non-Small-Cell Lung Cancer

Great progress has been made in the treatment of driver gene-positive Non- Small Cell Lung Cancer (NSCLC) in recent years. RET fusion was seen in 0.7% to 2% of NSCLC and was associated with younger age and never-smoker status. The pralsetinib and selpercatinib for RET fusion NSCLC was recommended by...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Lu, Mei, Qingyun, Yu, Yongchao, Wang, Na, Zhang, Dou, Liao, Dongying, Zuo, Jinhui, Xie, Hongxia, Jia, Yingjie, Kong, Fanming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9190697/
https://www.ncbi.nlm.nih.gov/pubmed/35707347
http://dx.doi.org/10.3389/fonc.2022.894214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9190697/
https://www.ncbi.nlm.nih.gov/pubmed/35707347
http://dx.doi.org/10.3389/fonc.2022.894214

Ejemplares similares